Apyx Medical Q3 revenue up 31% to $12.0M; cuts FY2023 revenue guidance sharply

Apyx Medical Corp

2023-Q3 EPS reported -$0.26 revenue$37,687,000

Q3 Advanced Energy revenue $9.8M (+39%); total revenue $12.0M (+31%); net loss $4.6M improved 20% YoY.
Cuts FY2023 revenue guidance to $53-54M from $59-62M; Advanced Energy now $44.5-45.5M from $51-54M.
Secured $45M credit facility with Perceptive; initial $37.5M funded; used to repay MidCap debt.
CFO Tara Semb to leave; successor identified but not named; departure not due to disagreement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Apyx Medical Corp reported the third quarter ended September 30, 2023 results: revenue $12.0 million, net income Net loss attributable to stockholders of $4.6 million. Guidance reaffirmed.

Period: the third quarter ended September 30, 2023
Revenue: $12.0 million
Net income: Net loss attributable to stockholders of $4.6 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

quarter ended September 30, 2023, and updated its financial expectations for the full year ending December 31, 2023. Third Quarter 2023 Financial Summary : • Total revenue of $12.0 million, up 31% year-over-year. ◦ Advanced Energy revenue of $9.8 million, up 39% year-over-year. ◦ OEM revenue of $2.1 million, up 5% year-over-year. • Net loss attributable to

View on SEC.gov

Browse all earnings releases →

Apyx Medical Corp filing history →

Source: SEC EDGAR

accession 0000719135-23-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.